Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 V617F JAK2 R947Q |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 R947Q | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 R947Q | hematologic cancer | sensitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915). | 39091915 | |
JAK2 V617F JAK2 R947Q | hematologic cancer | sensitive | Lestaurtinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of a cell line expressing JAK2 V617F and R947Q in culture (PMID: 39091915). | 39091915 |